Abstract:Objective Polygenic risk scores (PRSs) derived from genome-wide association studies are strong predictors of colorectal cancer (CRC) risk. We applied the straightforward approach of risk advancement periods (RAPs) to derive risk-adapted starting ages of CRC screening according to sex and PRS in the UK Biobank. Methods Among 242,779 participants (40-69 years; no previous CRC screening; no family history of CRC), we assessed associations of sex and a PRS with CRC risk and mortality using Cox regression models. Hazard ratios (HRs) were translated to RAPs to quantify how many years of age earlier men and women in defined PRS deciles reach comparable risks as those in the reference group (5th and 6th PRS deciles). Results During a median follow-up of 11.2 and 12.8 years, 2,714 participants were diagnosed with CRC and 758 died from CRC, respectively. HRs (95% CIs) of CRC risk were 1.57 (1.46, 1.70) for men versus women and ranged from 0.51 (0.41, 0.62) to 2.29 (2.01, 2.62) across PRS deciles compared to the reference. RAPs (95% CI) were 5.6 (4.6, 6.6) years for men versus women, and ranged from -8.4 (-11.0, -5.9) to 10.3 (8.5, 12.1) years across PRS deciles compared to the reference. Risk-adapted starting ages would vary by 24 years between men in the highest PRS decile and women in the lowest PRS decile. Very similar results were obtained regarding CRC mortality. Conclusion Consideration of sex and a standard PRS alone could have far-reaching implications for starting ages of CRC screening in the “average risk population”. What is already known on this topic What this study adds How this study might affect research, practice or policy ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported in part by the German Cancer Aid (Deutsche Krebshilfe, grant no. 70113330). The sponsors had no role in the study design and in the collection, analysis, and interpretation of data. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The UK Biobank study has obtained approval from the North West Multi-center Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval (renewed approval in 2021: 21/NW/0157). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes This work used data provided by patients and collected by the NHS as part of their care and support. The UK Biobank is an open-access resource and bona fide researchers can apply to use the UK Biobank dataset by registering and applying at <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Further information is available from the corresponding author upon request.

Preventing premature deaths through polygenic risk scores

Utility of polygenic risk scores in UK cancer screening: a modelling analysis

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Polygenic Risk Score Implementation into Clinical Practice for Primary Prevention of Cardiometabolic Disease

Implementing polygenic risk scores in the clinic

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Polygenic risk scores: from research tools to clinical instruments

Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Polygenic risk scores for the prediction of cardiometabolic disease

Using risk advancement periods to derive starting ages of colorectal cancer screening according to sex and polygenic risk score: Results from the UK Biobank

Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction

Methodologies underpinning polygenic risk scores estimation: a comprehensive overview

Assessing the value of incorporating a polygenic risk score with non-genetic factors for predicting breast cancer diagnosis in the UK Biobank

Combining European Society of Cardiology and American College of Cardiology/American Heart Association risk prediction model with polygenic risk scores to refine cardiovascular prevention

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Early Prediction of Prostate Cancer Risk in Younger Men Using Polygenic Risk Scores and Electronic Health Records

A unified framework for estimating country-specific cumulative incidence for 18 diseases stratified by polygenic risk

Evaluating the cost-effectiveness of polygenic risk score-stratified screening for abdominal aortic aneurysm

Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events